Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Fuso: Operating Profits Down 56.6%
November 23, 2009
- Univ. Hospitals Should Use More Generics: Mr Isobe
November 23, 2009
- Banyu to Boost Its Vaccine Business with Pneumovax, Gardasil
November 16, 2009
- InCROM to Conduct Mock PI Trials for Drug Makers’Employees
November 16, 2009
- GSK to Promote Cervarix Targeting All Dept. and Deploying over 1,000 MRs
November 16, 2009
- Hospira Japan Launches GemStar PCA Pump
November 16, 2009
- Medipal to Further Drug Distribution System Reform
November 16, 2009
- Quintiles Is More Than a CRO: Dr Winstanly
November 16, 2009
- Alfresa to Begin Business in China in Earnest
November 16, 2009
- Eisai Reshuffles R&D System to Speed Up Development of Anticancer Drugs
November 16, 2009
- Big Changes in Style of Discussions at Chuikyo
November 16, 2009
- Strong Yen Hit Top-Eight Domestic Companies’Performance
November 16, 2009
- Pricing Rule to Be Revised for New Products Containing Existing API: Chuikyo
November 16, 2009
- Half-Year Business Results of Domestic Companies: 2 （１）
November 16, 2009
- Share of Original Drugs Not Decreasing Much in Japan Despite Large Fall in Prices: Korosho Survey
November 16, 2009
- Half-Year Business Results of Domestic Companies: 2 （２）
November 16, 2009
- Korosho Considers Revising Medical Fees to Induce Doctors to Prescribe Fewer Antipsychotics
November 16, 2009
- Deeply Cut Prices of New Drugs to Save Failing Healthcare System: Hodanren
November 16, 2009
- REGULATORY NEWS IN BRIEF
November 16, 2009
- Takeda Ties Up with Amylin for Treatment of Obesity
November 16, 2009
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…